Drug intelligence / Profile preview

Optive and Systane

Development stage
Unknown
Lead developer
Janssen Pharmaceutical
Modality
Small Molecules
Administration
Ophthalmic
01

Overview

This entry refers to a Phase 4 clinical trial comparison between two over-the-counter lubricant eye drop products, **Optive** and **Systane**, conducted by Innovative Medical for the treatment of dry eye syndrome. Optive, developed by Allergan, contains carboxymethylcellulose sodium and glycerin as its active ingredients. Systane, developed by Alcon, contains polyethylene glycol and propylene glycol. Both products are artificial tear formulations that function as small molecule lubricants to mechanically supplement the tear film, providing hydration and protection to the ocular surface. The trial specifically evaluated the subjective duration of action and frequency of use of these two products when used concomitantly with topical cyclosporine (Restasis) in patients with mild to moderate dry eye disease. Neither product targets a specific biological receptor; instead, they work mechanically to relieve symptoms such as dryness, irritation, and discomfort.

Brand names
OptiveSystane
Other names
Optive, Systane-Innovative Medical-dry eye syndromeOptive vs Systane Frequency of Use in Dry Eye

Beyond the preview

Go deeper on Optive and Systane.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Optive and Systane.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call